Home / Companies / News / Covid-19 crisis: Briton Pharma gets DCGI nod to launch favipiravir

Covid-19 crisis: Briton Pharma gets DCGI nod to launch favipiravir

Pune-based Brinton Pharmaceuticals said on Thursday it had got the nod from the Drugs Controller General of India (DCGI) to market its brand Faviton, priced at Rs 59 per tablet

Glenmark has completed phase-III clinical studies, with favipiravir in mild-to-moderate Covid-19 patients in India.

Premium

Brinton will also be exporting Faviton globally.

1 min read Last Updated : Jul 24 2020 | 1:35 AM IST

After Glenmark’s Fabiflu, a second favipiravir—an oral antiviral drug used in Covid-19 treatment—has got approval from the drugs regulator.

Pune-based Brinton Pharmaceuticals said on Thursday it had got the nod from the Drugs Controller General of India (DCGI) to market its brand Faviton, priced at Rs 59 per tablet.

Faviton will be available in a strip of 10 tablets and in a box of 50 tablets. It will be available in 200 mg tablets.

Brinton will also be exporting Faviton globally.

”Emerging favorable global clinical evidence suggests, Favipiravir is an effective treatment option in the management of mild to moderate Covid-19. As this is

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in